Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7111 to 7125 of 7710 results

  1. Ovarian cancer - topotecan (TA28)

    This guidance has been replaced by NICE technology appraisal guidance 91.

    Technology appraisal guidance
    Published
    23 July 2001

  2. Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA280)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    24 April 2013

  3. Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

    This guidance has been updated and replaced by NICE guideline NG219.

    Technology appraisal guidance
    Published
    24 April 2013

  4. Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)

    This guidance has been updated and replaced by NICE technology appraisal guidance 504.

    Technology appraisal guidance
    Published
    24 April 2013

  5. Ustekinumab for treating active psoriatic arthritis (TA313)

    This guidance has been updated and replaced by NICE technology appraisal guidance 340.

    Technology appraisal guidance
    Published
    27 May 2014

  6. Bosutinib for previously treated chronic myeloid leukaemia (TA299)

    This guidance has been updated and replaced by NICE technology appraisal guidance 401. 

    Technology appraisal guidance
    Published
    27 November 2013

  7. Ovarian cancer - taxanes (TA3)

    This guidance has been replaced by NICE technology appraisal guidance 55. 

    Technology appraisal guidance
    Published
    27 May 2000

  8. Taxanes for the treatment of breast cancer (TA30)

    This guidance has been replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    26 September 2001

  9. Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)

    The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.

    Technology appraisal guidance
    Published
    26 June 2013

  10. Lubiprostone for treating chronic idiopathic constipation (TA318)

    This guidance has been withdrawn because Takeda has discontinued lubiprostone (Amitiza).

    Technology appraisal guidance
    Published
    23 July 2014

  11. Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (TA295)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA421.

    Technology appraisal guidance
    Published
    28 August 2013

  12. Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene (TA296)

    This guideance has been updated and replaced by NICE technology appraisal guidance 422.

    Technology appraisal guidance
    Published
    25 September 2013

  13. Ocriplasmin for treating vitreomacular traction (TA297)

    We have withdrawn this guidance. Inceptua has stopped marketing Ocriplasmin (Jetrea) and its marketing authorisation has been withdrawn.

    Technology appraisal guidance
    Published
    23 October 2013

  14. Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (TA309)

    This guidance has been updated and replaced by NICE technology appraisal guidance 402.

    Technology appraisal guidance
    Published
    23 April 2014

  15. The clinical effectiveness and cost effectiveness of sibutramine for obesity (TA31)

    This guidance has been replaced by NICE guideline CG43. 

    Technology appraisal guidance
    Published
    28 October 2001